Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Market Closed - Nasdaq
Other stock markets
 21:30:01 20/05/2024 BST 		5-day change 1st Jan Change
0.755 USD +0.53% Intraday chart for Lipella Pharmaceuticals Inc. +3.04% -25.98%
05-09 Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-17 Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
AQ
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
AQ
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
AQ
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
AQ
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
AQ
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
AQ
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
AQ
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
PR
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
PR
Lipella Pharmaceuticals Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
AQ
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
PR
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
PR
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
PR
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
PR
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
PR
Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. News Lipella Pharmaceuticals Inc.
  5. Press Releases